Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer

The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets

(2012) Andrew Wiemer et al.   Anti-Cancer Agents in Medicinal Chemistry

Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: a case-control study

(2009) M. ETMINAN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases

(2009) In Hae Park et al.   BMC CANCER

Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells

(2009) Tilman D. Rachner et al.   CANCER LETTERS

Osteoporosis treatments and adverse events

(2009) Daniel H Solomon et al.   CURRENT OPINION IN RHEUMATOLOGY

Bisphosphonates and Atrial Fibrillation

(2009) Yoon Kong Loke et al.   DRUG SAFETY

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

(2008) Nigel J. Bundred et al.   CANCER

Hip bone density predicts breast cancer risk independently of Gail score

(2008) Zhao Chen et al.   CANCER

Emerging role of bisphosphonates in the clinic—Antitumor activity and prevention of metastasis to bone

(2008) Allan Lipton   CANCER TREATMENT REVIEWS

Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio

(2008) P. Valverde   CURRENT MEDICINAL CHEMISTRY

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy

(2008) R. G. G. Russell et al.   OSTEOPOROSIS INTERNATIONAL